CXCR3 and COVID-19: Similarly to CCR6 expression, CCR6+CXCR3– Tc17 cells were primarily identified within CM and EM CD8+ T cell subsets, and the percentage of Tc17 cells was higher during acute SARS-CoV-2 infection, as well as in COVID-19 convalescents, than in healthy controls (2.63% (1.73; 4.36) and 3.16% (1.50; 4.73) vs. 1.66% (1.03; 3.30) with p = 0.007 and p = 0.010, respectively, for CM subsets, and 8.13% (4.15; 16.75) and 8.46% (4.64; 14.27) vs. 3.86% (2.23; 7.51), p < 0.001 in both cases for the EM CD8+ T cell subset).